BR112020023946A2 - composto heterocíclico, e, composição farmacêutica. - Google Patents
composto heterocíclico, e, composição farmacêutica. Download PDFInfo
- Publication number
- BR112020023946A2 BR112020023946A2 BR112020023946-1A BR112020023946A BR112020023946A2 BR 112020023946 A2 BR112020023946 A2 BR 112020023946A2 BR 112020023946 A BR112020023946 A BR 112020023946A BR 112020023946 A2 BR112020023946 A2 BR 112020023946A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazin
- pyrido
- bromo
- imidazo
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0062254 | 2018-05-31 | ||
| KR20180062254 | 2018-05-31 | ||
| PCT/KR2019/006553 WO2019231270A1 (en) | 2018-05-31 | 2019-05-31 | Heterocyclic derivatives and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020023946A2 true BR112020023946A2 (pt) | 2021-02-23 |
Family
ID=68698381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020023946-1A BR112020023946A2 (pt) | 2018-05-31 | 2019-05-31 | composto heterocíclico, e, composição farmacêutica. |
Country Status (12)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| EP4067357A1 (en) * | 2021-03-30 | 2022-10-05 | JW Pharmaceutical Corporation | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate |
| CN113929634A (zh) * | 2021-11-22 | 2022-01-14 | 山西永津集团有限公司 | 一种2,3-二溴喹喔啉的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE358395B (cg-RX-API-DMAC7.html) * | 1967-09-27 | 1973-07-30 | Siegfried Ag | |
| EP1613629A1 (en) * | 2003-03-27 | 2006-01-11 | Pfizer Products Inc. | Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines |
| JP2012502067A (ja) * | 2008-09-10 | 2012-01-26 | カリプシス・インコーポレーテッド | 疾患の治療のためのヒスタミン受容体の複素環阻害剤 |
| TW201204727A (en) * | 2010-03-10 | 2012-02-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| TW201206936A (en) * | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
| CN103889986B (zh) * | 2011-09-30 | 2017-07-21 | C&C新药研究所 | 新杂环衍生物及其应用 |
| WO2014152029A2 (en) * | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| US10407423B2 (en) * | 2015-11-16 | 2019-09-10 | Fundación Para La Investigación Médica Aplicada | Compounds as inhibitors of DNA methyltransferases |
| JP7212612B2 (ja) * | 2016-07-28 | 2023-01-25 | プロメガ コーポレイション | セレンテラジン類縁体 |
-
2019
- 2019-05-30 TW TW108118749A patent/TW202021969A/zh unknown
- 2019-05-31 US US17/057,753 patent/US20210198259A1/en not_active Abandoned
- 2019-05-31 JP JP2020566706A patent/JP2021525738A/ja not_active Withdrawn
- 2019-05-31 WO PCT/KR2019/006553 patent/WO2019231270A1/en not_active Ceased
- 2019-05-31 AU AU2019279421A patent/AU2019279421A1/en not_active Abandoned
- 2019-05-31 CN CN201980035540.4A patent/CN112204032A/zh active Pending
- 2019-05-31 EP EP19810281.6A patent/EP3807282A4/en not_active Withdrawn
- 2019-05-31 KR KR1020190064284A patent/KR102344295B1/ko not_active Expired - Fee Related
- 2019-05-31 MX MX2020011955A patent/MX2020011955A/es unknown
- 2019-05-31 BR BR112020023946-1A patent/BR112020023946A2/pt not_active Application Discontinuation
- 2019-05-31 SG SG11202010985TA patent/SG11202010985TA/en unknown
- 2019-05-31 CA CA3098825A patent/CA3098825A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3807282A4 (en) | 2022-03-02 |
| US20210198259A1 (en) | 2021-07-01 |
| KR102344295B1 (ko) | 2021-12-29 |
| CA3098825A1 (en) | 2019-12-05 |
| SG11202010985TA (en) | 2020-12-30 |
| EP3807282A1 (en) | 2021-04-21 |
| TW202021969A (zh) | 2020-06-16 |
| KR20190137013A (ko) | 2019-12-10 |
| CN112204032A (zh) | 2021-01-08 |
| JP2021525738A (ja) | 2021-09-27 |
| MX2020011955A (es) | 2021-01-15 |
| AU2019279421A1 (en) | 2020-12-03 |
| WO2019231270A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247027B2 (en) | P2X7 modulators | |
| US10077243B2 (en) | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | |
| CN107660205B (zh) | 作为lsd1抑制剂的杂环化合物 | |
| US10513523B2 (en) | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | |
| WO2014133022A1 (ja) | テトラヒドロイミダゾ[1,5-d][1,4]オキサゼピン誘導体 | |
| TW202104223A (zh) | 磷脂醯肌醇3-激酶抑制劑 | |
| KR20220079919A (ko) | 헤테로시클릭 rip1 억제 화합물 | |
| EP2493895A1 (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| US20220315597A1 (en) | Tricyclic compounds and their use | |
| CA2848154A1 (en) | Novel heterocyclic derivatives and their uses | |
| KR102344295B1 (ko) | 헤테로사이클 유도체 및 이의 용도 | |
| WO2019031990A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
| BR112019017058A2 (pt) | compostos como inibidores de pde1, composição farmacêutica e uso dos mesmos | |
| JP7551607B2 (ja) | アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体 | |
| JP2021525738A5 (cg-RX-API-DMAC7.html) | ||
| HK40034987A (en) | Heterocyclic derivatives and use thereof | |
| CN120441568A (zh) | 作为Cbl-b抑制剂的化合物及其应用 | |
| BR112020018983A2 (pt) | Inibidores de canal receptor de potencial transitório de oxadiazol | |
| HK1172327B (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| BR122020017743B1 (pt) | Processo para fabricação de uma composição farmacêutica e uso de uma composição farmacêutica | |
| CN105579459A (zh) | 四并环类间变性淋巴瘤激酶抑制剂 | |
| BR112014010459B1 (pt) | Compostos e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |